Opaleye Management Inc. 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Opaleye Management Inc. disclosed 44 US equity positions worth $599.6m in its Q3 2024 13F filing. The largest position was HROW at 29.9% of the reported book, followed by TGTX and OCUL.
What did Opaleye Management Inc. own in Q3 2024? Top 44 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | HROW HARROW HEALTH INC | 29.9% | $179.4m | 3,990,000 | – | ||
| 2 | TGTX TG THERAPEUTICS INC | Healthcare | 8.9% | $53.3m | 2,280,000 | – | |
| 3 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 7.3% | $43.7m | 5,025,000 | – | |
| 4 | ARVN ARVINAS INC | Healthcare | 5.2% | $30.9m | 1,255,000 | – | |
| 5 | CDXS CODEXIS INC | Healthcare | 4.5% | $27.0m | 8,770,000 | – | |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 4.4% | $26.2m | 500,000 | – | |
| 7 | KROS KEROS THERAPEUTICS INC | Healthcare | 3.8% | $23.0m | 395,276 | – | |
| 8 | IMNM IMMUNOME INC | Healthcare | 3.0% | $18.1m | 1,237,500 | – | |
| 9 | LQDA LIQUIDIA CORPORATION | Healthcare | 2.8% | $17.0m | 1,698,142 | – | |
| 10 | ETON ETON PHARMACEUTICALS INC | 2.8% | $16.7m | 2,780,000 | – | ||
| 11 | EWTX EDGEWISE THERAPEUTICS INC | 2.3% | $13.9m | 522,500 | – | ||
| 12 | CRGX CARGO THERAPEUTICS INC | 2.0% | $11.8m | 541,437 | – | ||
| 13 | APLT APPLIED THERAPEUTICS INC' | 1.9% | $11.2m | 1,320,000 | – | ||
| 14 | PCVX VAXCYTE INC | Healthcare | 1.6% | $9.7m | 85,000 | – | |
| 15 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.6% | $9.4m | 420,000 | – | |
| 16 | ACELYRIN INC | 1.6% | $9.3m | 1,893,660 | – | ||
| 17 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.4% | $8.6m | 2,567,990 | – | |
| 18 | BDSX BIODESIX INC | 1.2% | $7.0m | 3,815,000 | – | ||
| 19 | DNA GINKGO BIOWORKS HOLDINGS | 1.1% | $6.7m | 820,202 | – | ||
| 20 | JSPR JASPER THERAPEUTICS INC | 1.1% | $6.6m | 353,500 | – | ||
| 21 | XOMA CORP DEL | 1.1% | $6.6m | 250,000 | – | ||
| 22 | NUVALENT INC | 1.1% | $6.5m | 64,000 | – | ||
| 23 | NEWAMSTERDAM PHARMA COMPANY | 0.9% | $5.6m | 335,000 | – | ||
| 24 | URGN UROGEN PHARMA LTD | Healthcare | 0.9% | $5.1m | 404,100 | – | |
| 25 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 0.8% | $4.7m | 105,000 | – | |
| 26 | GOSSAMER BIO INC | 0.7% | $4.2m | 8,000,000 | – | ||
| 27 | CYTK CYTOKINETICS INC | Healthcare | 0.7% | $4.0m | 75,300 | – | |
| 28 | KARYOPHARM THERAPEUTICS INC | 0.7% | $4.0m | 6,000,000 | – | ||
| 29 | GOSS GOSSAMER BIO INC | Healthcare | 0.6% | $3.7m | 3,665,010 | – | |
| 30 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 0.6% | $3.6m | 967,000 | – | |
| 31 | TARA PROTARA THERAPEUTICS INC | 0.5% | $3.1m | 1,681,154 | – | ||
| 32 | RZLT REZOLUTE INC | 0.4% | $2.3m | 466,563 | – | ||
| 33 | CATALYST PHARMACEUTICALS INC | 0.4% | $2.2m | 112,500 | – | ||
| 34 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 0.3% | $2.1m | 800,000 | – | |
| 35 | LYEL LYELL IMMUNOPHARMA INC | 0.3% | $1.9m | 1,395,000 | – | ||
| 36 | ALLKGUSD ALLAKOS INC | 0.3% | $1.6m | 2,407,600 | – | ||
| 37 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.3% | $1.6m | 480,000 | – | |
| 38 | PEPG PEPGEN INC | Healthcare | 0.3% | $1.5m | 179,200 | – | |
| 39 | RVNCEUR REVANCE THERAPEUTICS INC | 0.2% | $1.4m | 275,000 | – | ||
| 40 | SYRS SYROS PHARMACEUTICALS INC | 0.2% | $1.4m | 654,943 | – | ||
| 41 | AEROVATE THERAPEUTICS INC | 0.2% | $919.6k | 440,000 | – | ||
| 42 | RGLS REGULUS THERAPEUTICS INC | 0.1% | $840.0k | 535,000 | – | ||
| 43 | IBIO IBIO INC | 0.1% | $832.5k | 375,000 | – | ||
| 44 | ADGM ADAGIO MED HLDGS INC | 0.0% | $285.3k | 110,571 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.